M. Littlejohn

P. Angus, A. Sheil, S. Locarnini, 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

HBV variants are common in the ‘immune‐tolerant’ phase of chronic hepatitis B

K. Kitrinos, A. Gaggar, P. Revill, 2020, Journal of viral hepatitis.

The in vitro replication phenotype of hepatitis B virus (HBV) splice variant Sp1.

P. Revill, M. Littlejohn, V. Sozzi, 2022, Virology.

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

S. Lewin, K. Ruxrungtham, C. Thio, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging.

S. Locarnini, J. Feld, D. Colledge, 2007, Antiviral research.

The evolution and clinical impact of hepatitis B virus genome diversity

H. Netter, P. Revill, S. Locarnini, 2020, Nature Reviews Gastroenterology & Hepatology.

Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance

S. Lewin, K. Ruxrungtham, P. Angus, 2008, Hepatology.

SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B.

S. Locarnini, D. Colledge, L. Yuen, 2007, Antiviral research.

HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing.

S. Lewin, K. Ruxrungtham, C. Thio, 2010, Virology.

In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes

P. Revill, N. Warner, S. Locarnini, 2016, Journal of Virology.

Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

S. Lewin, S. Locarnini, E. Gane, 2010, Hepatology.

482 Molecular analysis of HBV polymerase mutations associated with dual adefovir and lamivudine resistance

P. Angus, N. Warner, M. Kuiper, 2006 .

Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B

M. Buti, P. Marcellin, R. Hammond, 2016, Gut.

Possible origins and evolution of the hepatitis B virus (HBV).

S. Locarnini, L. Yuen, M. Littlejohn, 2013, Seminars in cancer biology.

Preventing early childhood transmission of hepatitis B in remote aboriginal communities in Northern Australia

S. Tong, Joshua S. Davis, J. Davies, 2022, International Journal for Equity in Health.

Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus.

S. Locarnini, L. Yuen, M. Littlejohn, 2016, Cold Spring Harbor perspectives in medicine.

Origins and Evolution of the Primate Hepatitis B Virus

S. Locarnini, L. Yuen, M. Littlejohn, 2021, Frontiers in Microbiology.

Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia.

S. Tong, S. Locarnini, N. Wood, 2018, Vaccine.

Molecular and clinical characteristics of hepatitis B virus in Korea

P. Revill, S. Locarnini, J. Heo, 2010, Journal of medical virology.

[505] MULTIDRUG RESISTANCE AND CROSS-RESISTANCE PATHWAYS IN HBV AS A CONSEQUENCE OF TREATMENT FAILURE

S. Locarnini, L. Yuen, M. Littlejohn, 2007 .

Factors Associated with Elevated ALT in an International HIV/HBV Co-Infected Cohort on Long-Term HAART

S. Lewin, K. Ruxrungtham, C. Thio, 2011, PloS one.

Molecular virology of hepatitis B virus, sub‐genotype C4 in northern Australian Indigenous populations

B. Cowie, S. Tong, S. Locarnini, 2014, Journal of medical virology.

Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?

S. Lewin, J. Sasadeusz, S. Bowden, 2020, Journal of acquired immune deficiency syndromes.

Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase

P. Marcellin, H. Janssen, A. Gaggar, 2020, Hepatology.

Insights From Deep Sequencing of the HBV Genome—Unique, Tiny, and Misunderstood

J. McKeating, M. Ansari, P. Revill, 2018, Gastroenterology.

Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome.

P. Revill, S. Locarnini, W. Hardikar, 2018, The Journal of general virology.

Hepatitis B and D in the Pacific Islands of Kiribati.

S. Locarnini, S. Nicholson, K. Jackson, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Hepatitis Delta Virus (HDV) and Delta-Like Agents: Insights Into Their Origin

Marilou H. Barrios, H. Netter, L. Yuen, 2021, Frontiers in Microbiology.

Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals

S. Lewin, K. Ruxrungtham, G. Dore, 2013, PloS one.

Tracing Ancient Human Migrations into Sahul Using Hepatitis B Virus Genomes.

S. Tong, S. Locarnini, S. Duchêne, 2019, Molecular biology and evolution.

Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia

S. Tong, S. Locarnini, Joshua S. Davis, 2019, Journal of viral hepatitis.

A Divergent Hepatitis D-Like Agent in Birds

M. Shi, E. Holmes, A. Hurt, 2018, bioRxiv.

Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B

P. Marcellin, H. Janssen, A. Gaggar, 2022, Alimentary pharmacology & therapeutics.

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients

M. Buti, P. Marcellin, H. Janssen, 2018, Alimentary pharmacology & therapeutics.

Targets for inhibition of hepatitis C virus replication.

M. Littlejohn, A. Bartholomeusz, S. Locarnini, 1998, Antiviral therapy.

Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues—authors' reply

P. Revill, M. Littlejohn, Josef Wagner, 2023, Alimentary pharmacology & therapeutics.

Treatment of Chronically HBV-Infected Chimpanzees with RNA Interference Therapeutic ARC-520 LED to Potent Reduction of Viral MRNA, DNA and Proteins without Observed Drug Resistance

S. Kanner, D. Lewis, R. Gish, 2016 .

Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants

V. Sundararajan, M. Sinclair, P. Revill, 2023, Hepatology communications.

TITLE : HBV variants are common in the “ immune-tolerant ” phase of chronic hepatitis B 11 Running Title : HBV variants in immune-tolerant phase 12 *

K. Kitrinos, A. Gaggar, P. Revill, 2020 .

Molecular epidemiology of hepatitis delta virus in the Western Pacific region.

Q. Ning, S. Locarnini, S. Bowden, 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.